课题基金 / 基金详情

Development/production of universal influenza vaccines

Development/production of universal influenza vaccines
通用流感疫苗的开发/生产
批准号：
8336678
负责人：
Richard Schwartz
金额：
$182.96万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8336678
关键词：
ClinicClinical TrialsContractsDNA VaccinesDevelopmentEvaluationHumanHuman VolunteersImmunityInfluenzaLaboratoriesNational Institute of Allergy and Infectious DiseasePhasePhase II Clinical TrialsPlacebosPlantsProductionSafetySeasonsTechniquesTestingVaccine ProductionVaccinesVirusclinical materialimmunogenicityinfluenza virus vaccinemanufacturing processpreclinical safetyprogramssafety study

项目摘要

项目成果

Richard Schwartz的其他基金

相似基金

相关文献

中文摘要
翻译
对多种病毒具有免疫力的流感疫苗将按照当前的良好制造规范(CGMP)生产用于人体临床试验，并在健康的人体志愿者身上发布用于人体临床试验。人们希望，这些疫苗将在几年内对多种毒株产生免疫力，而不是季节性产品，因为季节性产品只对一个季节有效。如果这些试验在人体试验中证明了该疫苗的安全性和免疫原性，可能会在更大规模的(第二阶段)试验中进行进一步的评估，这将需要大规模生产临床试验材料(CTM)。
英文摘要
Influenza vaccines conferring immunity against multiple strains of virus will be manufactured for human clinical trials in compliance with current Good Manufacturing Practices (cGMP) and released for use in human clinical trials in healthy human volunteers. It is hoped that these vaccines will confer immunity over a period of several years against multiple strains in contrast to seasonal products that are only useful for a single season. If these trials demonstrate safety and immunogenicity of this vaccine in human trials, further evaluation may take place in larger (Phase 2) trials which will necessitate production of the clinical trial materials (CTM) at large scale.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development And Production Of Filovirus DNA Plasmid Vaccines
Production of a Broadly Neutralizing HIV Antibody (VRC01)
HIV LCMV vaccines
Production of a Broadly Neutralizing HIV Antibody (VRC01)
海外基金